Skip to main content

Advertisement

PSMA Targeted Imaging and Therapy: Prostate and Other Cancers

  1. Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in most patients. Five to 15% of patients be...

    Authors: Lisa H. de Vries, Lutske Lodewijk, Arthur J. A. T. Braat, Gerard C. Krijger, Gerlof D. Valk, Marnix G. E. H. Lam, Inne H. M. Borel Rinkes, Menno R. Vriens and Bart de Keizer

    Citation: EJNMMI Research 2020 10:18

    Content type: Preliminary research

    Published on:

  2. Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, refe...

    Authors: Cordula A. Jilg, Kathrin Reichel, Christian Stoykow, H. Christian Rischke, Mark Bartholomä, Vanessa Drendel, Moritz von Büren, Wolfgang Schultze-Seemann, Philipp T. Meyer and Michael Mix

    Citation: EJNMMI Research 2020 10:17

    Content type: Original research

    Published on:

  3. Prostate-specific membrane antigen (PSMA) ligand PET/CT has already provided promising results in prostate cancer (PC) imaging, yet simple and reproductible reporting criteria are still lacking. This study aim...

    Authors: Céline Derwael, Olivier Lavergne, Pierre Lovinfosse, Vlad Nechifor, Mallory Salvé, David Waltregny, Roland Hustinx and Nadia Withofs

    Citation: EJNMMI Research 2020 10:15

    Content type: Original research

    Published on:

  4. Several scan parameters for PET imaging with 18F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide admi...

    Authors: Sarah Piron, Kathia De Man, Vanessa Schelfhout, Nick Van Laeken, Ken Kersemans, Eric Achten, Filip De Vos and Piet Ost

    Citation: EJNMMI Research 2020 10:14

    Content type: Original research

    Published on:

  5. The positron emission tomography (PET) ligand 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although 68Ga-PSMA-11 PET i...

    Authors: Anna Ringheim, Guilherme de Carvalho Campos Neto, Udunna Anazodo, Lumeng Cui, Marcelo Livorsi da Cunha, Taise Vitor, Karine Minaif Martins, Ana Cláudia Camargo Miranda, Marycel Figols de Barboza, Leonardo Lima Fuscaldi, Gustavo Caserta Lemos, José Roberto Colombo Junior and Ronaldo Hueb Baroni

    Citation: EJNMMI Research 2020 10:12

    Content type: Original research

    Published on: